Does Δ133p53 isoform trigger inflammation and autoimmunity?

Cell Cycle

Volumn 11, Issue 3, 2012, Pages 446-450

  Campbell, Hamish G ^a   Slatter, Tania L ^b   Jeffs, Aaron ^b   Mehta, Reena ^a   Rubio, Carina ^a   Baird, Margaret ^c   Braithwaite, Antony W ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Autoimmune; Delta133p53; Inflammation; P53; P53 isoforms

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; P21 ACTIVATED KINASE; PROTEIN P53; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD VESSEL; CELL AGGREGATION; CELL CYCLE ARREST; DNA REPAIR; EXTRAMEDULLARY HEMATOPOIESIS; GENE FREQUENCY; GRAVES DISEASE; HEPATITIS; HUMAN; INFLAMMATION; LUTEOMA; MICROARRAY ANALYSIS; NONHUMAN; PEYER PATCH; PHENOTYPE; PREGNANCY; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; WEGENER GRANULOMATOSIS; WILD TYPE;

EID: 84857218196     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.3.19054     Document Type: Review

References (33)

1. Medzhitov R. Origin and physiological roles of inf lammation. Nature 2008; 454:428-35; PMID:18650913; http://dx.doi.org/10.1038/nature07201.
2. Nathan C. Points of control in inflammation. Nature 2002; 420:846-52; PMID:12490957; http://dx.doi.org/10.1038/nature01320.
3. Medzhitov R. Inf lammation 2010: new adventures of an old flame. Cell 2010; 140:771-6; PMID:20303867; http://dx.doi.org/10.1016/j.cell.2010.03.006.
4. Braithwaite AW, Prives CL. p53: more research and more questions. Cell Death Differ 2006; 13:877- 80; PMID:16708075; http://dx.doi.org/10.1038/sj.cdd. 4401938.
5. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161; http://dx.doi.org/10.1038/nrm2147.
6. Braithwaite AW, Royds JA, Jackson P. The p53 story: layers of complexity. Carcinogenesis 2005; 26:1161- 9; PMID:15817608; http://dx.doi.org/10.1093/ carcin/ bgi091.
7. Sun Y, Cheung HS. p53, proto-oncogene and rheumatoid arthritis. Semin Arthritis Rheum 2002; 31:299- 310; PMID:11965594; http://dx.doi.org/10.1053/ sarh.2002.31550.
8. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997; 94:10895-900; PMID:9380731; http://dx.doi.org/10. 1073/pnas.94.20.10895.
9. Miret C, Molina R, Filella X, García-Carrasco M, Claver G, Ingelmo M, et al. Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity. Tumour Biol 2003; 24:185-8; PMID:14654712; http://dx.doi.org/10.1159/000074428.
10. Kuhn HM, Kromminga A, Flammann HT, Frey M, Layer P, Arndt R. p53 autoantibodies in patients with autoimmune diseases: a quantitative approach. Autoimmunity 1999; 31:229-35; PMID:10789988.
11. Herkel J, Mimran A, Erez N, Kam N, Lohse AW, Märker-Hermann E, et al. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. J Autoimmun 2001; 17:63-9; PMID:11488638; http://dx.doi. org/10.1006/jaut.2001.0518.
12. Herkel J, Modrow JP, Bamberger S, Kanzler S, Rotter V, Cohen IR, et al. Prevalence of autoantibodies to the p53 protein in autoimmune hepatitis. Autoimmunity 2002; 35:493-6; PMID:12765474; http://dx.doi.org/10.1080/ 0891693021000054075.
13. Kovacs B, Patel A, Hershey JN, Dennis GJ, Kirschfink M, Tsokos GC. Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 1997; 40:980-2; PMID:9153564; http:// dx.doi.org/10.1002/art.1780400531.
14. Kuan AP, Cohen PL. p53 is required for spontaneous autoantibody production in B6/lpr lupus mice. Eur J Immunol 2005; 35:1653-60; PMID:15789337; http://dx.doi.org/10.1002/eji.200525982.
15. Balomenos D, Martín-Caballero J, García MI, Prieto I, Flores JM, Serrano M, et al. The cell cycle inhibitor p21 controls T-cell proliferation and sexlinked lupus development. Nat Med 2000; 6:171-6; PMID:10655105; http://dx.doi.org/10.1038/72272.
16. Salvador JM, Hollander MC, Nguyen AT, Kopp JB, Barisoni L, Moore JK, et al. Mice lacking the p53-effector gene Gadd45a develop a lupuslike syndrome. Immunity 2002; 16:499-508; PMID:11970874; http://dx.doi.org/10.1016/S1074- 7613(02)00302-3.
17. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1991; 88:7605-9; PMID:1652755; http:// dx.doi.org/10.1073/pnas.88. 17.7605.
18. Zhang S, Zheng M, Kibe R, Huang Y, Marrero L, Warren S, et al. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J 2011; 25:2387-98; PMID:21471252; http://dx.doi. org/10.1096/fj.10-175299.
19. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1-20; PMID:12773095; http://dx.doi.org/10.1042/ BJ20030407.
20. Zheng SJ, Lamhamedi-Cherradi SE, Wang P, Xu LY, Chen YH. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 2005; 54:1423-8; PMID:15855329; http:// dx.doi.org/10.2337/diabetes.54.5.1423.
21. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002; 99:10025-30; PMID:12119414; http://dx.doi.org/10.1073/ pnas.152333199.
22. Drenkard C, Villa AR, Reyes E, Abello M, Alarcón- Segovia D. Vasculitis in systemic lupus erythematosus. Lupus 1997; 6:235-42; PMID:9104729; http:// dx.doi.org/10.1177/096120339700600304.
23. Mongan ES, Cass RM, Jacox RF, Vaughen JH. A study of the relation of seronegative and seropositive rheumatoid arthritis to each other and to necrotizing vasculitis. Am J Med 1969; 47:23-35; PMID:4183354; http://dx.doi.org/10.1016/0002- 9343(69)90238-1.
24. Slatter TL, Hung N, Campbell H, Rubio C, Mehta R, Renshaw P, et al. Hyperproliferation, cancer and inflammation in mice expressing a Δ133p53-like isoform. Blood 2011; 117:5166-77; PMID:21411755; http://dx.doi.org/10.1182/blood-2010-11-321851.
25. Slatter TL, Ganesan P, Holzhauer C, Mehta R, Rubio C, Williams G, et al. p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death Differ 2010; 17:540-50; PMID:19779492; http://dx.doi.org/10.1038/cdd.2009.136.
26. Pisetsky DS. The role of innate immunity in the induction of autoimmunity. Autoimmun Rev 2008; 8:69-72; PMID:18708168; http://dx.doi.org/10. 1016/j.autrev.2008.07.028.
27. Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67:1069-75; PMID:18063674; http://dx.doi.org/10.1136/ard.2007.074765.
28. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197:711-23; PMID:12642603; http://dx.doi.org/10.1084/jem. 20021553.
29. Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, et al. p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009; 11:1135- 42; PMID:19701195; http://dx.doi.org/10.1038/ncb1928.
30. Herkel J, Erez-Alon N, Mimran A, Wolkowicz R, Harmelin A, Ruiz P, et al. Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA. Eur J Immunol 2000; 30:977-84; PMID:10760784; http://dx.doi.org/10.1002/(SICI) 1521-4141(200004) 30 : 4 〈977: :AIDIMMU977〉 3.0.CO;2-A.
31. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002; 100:82-5; PMID:12115591; http://dx.doi.org/10.1002/ijc.10444.
32. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88:497-502; PMID:11054684; http://dx.doi.org/10.1002/1097-0215(20001101)88:3〈497::AID- IJC27〉3.0.CO;2-J.
33. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98:51-60; PMID:16391371; http://dx.doi.org/10.1093/jnci/djj004.